Researchers have published results that show that a new drug has very good potential to prevent malaria during pregnancy for women living with HIV.
According to a study christened, IMPROVE-2 by researchers from Kenya Medical Research Institute (KEMRI) in partnership with colleagues from the Liverpool School of Tropical Medicine (LSTM), the Kamuzu University of Health Sciences, and the Malawi University of Science and Technology published in The Lancet, suggests that the addition of the antimalarial drug dihydroartemisinin–piperaquine to daily co-trimoxazole substantially reduces the risk of malaria in pregnancy.
“We celebrate these findings that propose additional arsenal against a disease that risks about 70 percent of our population, malaria in pregnancy can cause a host of serious health complications, including miscarriage, stillbirth, pre-term delivery and growth restriction of newborn babies, and co-infection with HIV increases doubles these risks,” said Prof. Elijah Songok, KEMRI Ag. Director General and Chief Executive Officer (CEO).
Malaria during pregnancy can cause serious maternal and newborn health issues, especially in women living with HIV. The World Health Organization recommends daily doses of the antibiotic co-trimoxazole to prevent malaria in pregnant women living with HIV residing in areas with high malaria transmission. However, its efficacy in sub–Saharan Africa is threatened because malaria parasites are becoming increasingly resistant to the drug.
Feiko ter Kuile, Professor of Tropical Epidemiology at LSTM, and the study lead, said: “These are promising findings, and potentially welcome news in the future of prevention malaria among pregnant women living with HIV in areas where prevalence of the disease is high. Our trial showed that the addition of dihydroartemisinin–piperaquine to the currently recommended preventative treatment strategy for pregnant women living with HIV reduced malaria by 68percent.”
Dr. Hellen Barsosio, a Clinical Research Scientist from the KEMRI’s Centre for Global Health Research (CGHR), and lead author on the new paper published in The Lancet, said: “These findings are very encouraging. Not only did we find that adding dihydroartemisinin– piperaquine to co-trimoxazole was safe and prevented two out of every three malaria infections during pregnancy, it was also very well tolerated by pregnant women, which is very important when a drug is given for prevention. The study could lead to a much-needed policy change that could make a real difference in improving maternal and newborn health in Africa”.
Dr. Simon Kariuki, Head of Malaria Program from the KEMRI-CGHR said: “We hope that these findings, along with a similar trial being conducted in Gabon and Mozambique, will inform the malaria prevention guidelines from the World Health Organization and national health policies.”
